Mesoblast MESO
NASDAQ MESO
$17.32 +0.18 (+1.05%)
At close: Sep 4, 2026 · 4:00 PM EDT

Mesoblast (MESO) Free Cash Flow (2014 - 2023)

Mesoblast (MESO) posted Free Cash Flow of -$16.5 million for Q2 2023, down 1.49% sequentially from -$16.2 million in Q1 2023, and down 18.7% YoY from -$20.3 million in Q2 2022.

Analysis

Mesoblast (MESO) Free Cash Flow (2014 - 2023) Analysis & Trends

Mesoblast has reported Free Cash Flow for 8 years, with the latest figure at -$16.5 million in Q2 2023.

  • Quarterly Free Cash Flow fell 18.7% year-over-year to -$16.5 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was -$16.5 million (up 66.48% YoY) and the FY2025 annual result came in at -$50.7 million, down 4.0% from the prior year.
  • Free Cash Flow fell to -$16.5 million in Q2 2023 per MESO's latest filing, from -$16.2 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$1.3 million in Q4 2019 and troughed at -$30.6 million in Q4 2020.
  • A 5-year average of -$17.9 million and a median of -$17.3 million in 2021 frame the typical range for Free Cash Flow.
  • The sharpest annual moves came in 2020 and 2021: Free Cash Flow plunged 2199.25% in 2020, then surged 40.42% in 2021.
  • Over 5 years, Free Cash Flow stood at -$1.3 million in 2019, then slumped by 2199.25% to -$30.6 million in 2020, then surged by 40.42% to -$18.2 million in 2021, then climbed by 9.69% to -$16.5 million in 2022, then decreased by 0.23% to -$16.5 million in 2023.
  • According to Business Quant data, Free Cash Flow over the past three periods registered -$16.5 million, -$16.2 million, and -$16.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.01 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 572.80 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -563.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -389.61 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 437.80 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 292.04 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 477.44 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -95.09 Mn
10 Mesoblast 2.24 Bn 2.14 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 110.05 Mn
Mar 31, 2023 -77.73 Mn
Dec 31, 2022 16.45 Mn
Sep 30, 2022 14.29 Mn
Jun 30, 2022 -13.89 Mn
Mar 31, 2022 -15.52 Mn
Dec 31, 2021 -18.22 Mn
Sep 30, 2021 18.20 Mn
Jun 30, 2021 -18.92 Mn
Mar 31, 2021 -24.47 Mn
Dec 31, 2020 -30.58 Mn
Sep 30, 2020 -28.17 Mn
Mar 31, 2020 -36.78 Mn
Dec 31, 2019 -16.89 Mn
Sep 30, 2019 -15.56 Mn
Mar 31, 2019 -21.19 Mn
Dec 31, 2018 -1.96 Mn
Sep 30, 2018 -19.54 Mn
Jun 30, 2018 -20.19 Mn
Mar 31, 2018 -19.60 Mn